J&J (JNJ) to Recall Single Lot Of Johnson's Baby Powder in U.S. After Test Indicates Presence of Sub-trace Levels of Chrysotile Asbestos
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Actelion Pharmaceuticals Reports New OPSUMIT (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical & Functional Parameters in Patients with PAH
October 21, 2019 9:04 AM EDTActelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson (NYSE: JNJ), today announces new data evaluating initial combination therapy with OPSUMIT® (macitentan) and tadalafIl, a PDE5 inhibitor. Patients with pulmonary arterial hypertension (PAH, WHO Group 1) taking this combination showed hemodynamic improvement, as well as improvements in functional parameters and risk profiles. The combination was also well tolerated in these patients. The study data is being shared today at the CHEST Annual Meeting 2019, held October 19-23 in New Orleans, Louisiana.
The OPTIMA (cOmbination theraPy of maciTentan and tadalafIl in patients with... More
Johnson & Johnson (JNJ) Trades at Low, Down 5%
October 18, 2019 12:20 PM EDTJohnson & Johnson (NYSE: JNJ) Trades at Low, Down 5%
... MoreJ&J (JNJ) Extends Decline, Now Down 3.4% After Baby Powder Recall Tied to Traces of Asbestos
October 18, 2019 9:09 AM EDTJ&J (NYSE: JNJ) Extends Decline, Now Down 3.4% After Baby Powder Recall Tied to Traces of Asbestos
